Search Results for: 19

— Conference Call Scheduled for Thursday, May 4, 2017 at 4:30 p.m. EDT — ROCKVILLE, Md., April, 26, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational […]

— Study Results Further Support Advancement of SYN-005 into Clinical Trials for Treatment and Prevention of Pertussis — — Poster Presentations Planned for ECCMID and ESPID Conferences, Including Data from Prophylaxis Study — ROCKVILLE, Md., April 19, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome

ROCKVILLE, Md., March 7, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that Jeffrey Riley, President & Chief Executive Officer, is scheduled to present at the 29th Annual ROTH Conference being held March 12-15

— Company Highlights Clinical Successes of Late-stage Microbiome-focused Programs, Plans for Phase 3 Development — — Conference Call Today, March 2, 2017, at 4:30 p.m. (EST) — ROCKVILLE, Md., March 2, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health

— Conference Call Scheduled for Thursday, March 2, 2017 at 4:30 p.m. EST — ROCKVILLE, Md., Feb. 21, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, intends to report operational highlights and financial results for

ROCKVILLE, Md., Feb. 3, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics to preserve the microbiome to protect and restore the health of patients, announced today that Jeffrey Riley, CEO, is scheduled to present at the BIO CEO & Investor Conference on Monday, February 13, 2017, at 4:00 p.m.

— Enrollment in SYN-010 Pivotal Trial Will Be Open to All IBS-C Patients — ROCKVILLE, Md., Jan. 18, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today confirmed plans to initiate a Phase 2b/3 adaptive pivotal

— Presentation Planned for 9:30am (PT), Jan. 9, 2017 at Biotech Showcase in San Francisco — ROCKVILLE, Md., Jan. 5, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today announced positive topline data from its Phase 2b

– Granted Patent Provides Composition of Matter Protection for SYN-005 to at Least 2035 – ROCKVILLE, Md., Dec. 13, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics focused on the gut microbiome, today announced that the United States Patent Office has granted U.S. Patent No. 9,512,204 which provides

ROCKVILLE, Md., Dec. 1, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics focused on the gut microbiome, today announced that members of Synthetic Biologics’ executive leadership team will participate in two upcoming investor conferences: 2016 Jefferies Annual Microbiome Summit London, EnglandTuesday, December 13, 2016 Guggenheim Securities 4th Annual Boston Healthcare